CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
CytoDyn (OTCQB: CYDY), a clinical-stage biotech company developing leronlimab, has announced a schedule change for its presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The company's CFO, Robert E. Hoffman, will now present on Wednesday, September 10, 2025, at 9:00 AM EDT in New York City.
The presentation will showcase CytoDyn's progress with leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, which shows therapeutic potential across multiple indications. One-on-one meetings with management will be available throughout the conference, which runs from September 8-10, 2025.
CytoDyn (OTCQB: CYDY), una società biotech in fase clinica che sviluppa leronlimab, ha annunciato una variazione nel programma della sua presentazione al H.C. Wainwright 27th Annual Global Investment Conference. Il CFO dell'azienda, Robert E. Hoffman, terrà ora la presentazione il mercoledì 10 settembre 2025 alle 9:00 AM EDT a New York City.
La presentazione illustrerà i progressi di CytoDyn con leronlimab, un anticorpo monoclonale umanizzato di prima classe che bersaglia il recettore CCR5 e mostra potenziale terapeutico in diverse indicazioni. Durante la conferenza, che si svolge dall'8 al 10 settembre 2025, saranno disponibili incontri individuali con il management.
CytoDyn (OTCQB: CYDY), una biotecnológica en fase clínica que desarrolla leronlimab, ha anunciado un cambio en el horario de su presentación en la H.C. Wainwright 27th Annual Global Investment Conference. El CFO de la compañía, Robert E. Hoffman, presentará ahora el miércoles 10 de septiembre de 2025 a las 9:00 AM EDT en la ciudad de Nueva York.
La presentación mostrará los avances de CytoDyn con leronlimab, un anticuerpo monoclonal humanizado de primera clase dirigido al receptor CCR5, que demuestra potencial terapéutico en múltiples indicaciones. Habrá reuniones individuales con la dirección disponibles durante la conferencia, que se celebra del 8 al 10 de septiembre de 2025.
CytoDyn (OTCQB: CYDY), 렌론리맙(leronlimab)을 개발하는 임상 단계의 바이오텍 회사가 H.C. Wainwright 27th Annual Global Investment Conference 발표 일정 변경을 공지했습니다. 회사의 재무책임자(CFO)인 Robert E. Hoffman이 2025년 9월 10일 수요일 동부 표준시(EDT) 오전 9:00에 뉴욕시에서 발표를 진행합니다.
이번 발표에서는 CCR5 수용체를 표적으로 하는 1세대 인간화 단클론 항체인 렌론리맙의 진척 상황을 소개합니다. 렌론리맙은 여러 적응증에서 치료적 잠재력을 보이고 있습니다. 2025년 9월 8일부터 10일까지 열리는 컨퍼런스 기간 동안 경영진과의 일대일 미팅도 가능합니다.
CytoDyn (OTCQB: CYDY), une entreprise biotechnologique en phase clinique développant le leronlimab, a annoncé une modification du calendrier de sa présentation à la H.C. Wainwright 27th Annual Global Investment Conference. Le directeur financier de la société, Robert E. Hoffman, présentera désormais le mercredi 10 septembre 2025 à 9h00 EDT à New York.
La présentation mettra en avant les progrès de CytoDyn concernant le leronlimab, un anticorps monoclonal humanisé de première classe ciblant le récepteur CCR5, qui montre un potentiel thérapeutique dans plusieurs indications. Des réunions individuelles avec la direction seront disponibles pendant la conférence, qui se tient du 8 au 10 septembre 2025.
CytoDyn (OTCQB: CYDY), ein Biotech-Unternehmen in der klinischen Entwicklungsphase, das Leronlimab entwickelt, hat eine Änderung des Zeitplans für seine Präsentation auf der H.C. Wainwright 27th Annual Global Investment Conference angekündigt. Der CFO des Unternehmens, Robert E. Hoffman, wird nun am Mittwoch, den 10. September 2025, um 9:00 Uhr EDT in New York City präsentieren.
Die Präsentation wird CytoDyns Fortschritte mit Leronlimab vorstellen, einem First-in-Class humanisierten monoklonalen Antikörper, der den CCR5-Rezeptor anvisiert und therapeutisches Potenzial in mehreren Indikationen zeigt. Während der Konferenz, die vom 8. bis 10. September 2025 stattfindet, sind Einzelgespräche mit dem Management möglich.
- None.
- None.
VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a change of time for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, to Wednesday, September 10, at 9 a.m. EDT.
CytoDyn CFO, Robert E. Hoffman, will deliver a live company presentation and will be available for one-on-one meetings throughout the event, which is taking place September 8-10, 2025, in New York City.
Details of the presentation are now as follows:
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 10, 2025
Time: 9 a.m. EDT
Webcast: register here
About CytoDyn
CytoDyn is a clinical-stage biotechnology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders.
Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
For more information, please visit www.cytodyn.com and follow us on LinkedIn.
Investor Relations
CytoDyn Inc.
ir@cytodyn.com
Media Contacts
Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com
FAQ
When is CytoDyn (CYDY) presenting at the H.C. Wainwright Conference 2025?
Who will be presenting for CytoDyn at the H.C. Wainwright Conference?
What is CytoDyn's main product in development?
Will investors be able to meet with CytoDyn management at the conference?
